

Technology Advisory Committee D Interests Register

Galcanezumab for preventing migraine [ID1372]

Publication Date: 18/11/2020

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Giles Monnickendam	TAC D Committee member	Indirect non-financial	His employer [Vitaccess] is designing and conducting an observational study for Teva, involving the migraine indication and fremanezumab.	NA	28/08/2020	NA	It was agreed that this declaration would not prevent Mr Monnickendam from participating in this section of the meeting.
Dr Nicola Giffin	Clinical expert	Direct financial	She has received an honorarium from Novartis who market Erenumab	NA	04/12/2019	NA	It was agreed that this declaration would not prevent Dr Giffin from participating in this section of the meeting.
Dr Nicola Giffin	Clinical expert	Indirect financial	She has received travel, hospitality, and conference fees from Teva who market Fremanezumab	NA	04/12/2019	NA	It was agreed that this declaration would not prevent Dr Giffin from participating in this section of the meeting.